Stay updated with breaking news from Nancy Pryer. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Biotech startup Ambagon Therapeutics is taking a new approach to making elusive protein targets “druggable” by using molecular glues. The biotech has a pipeline of preclinical cancer drugs and it has raised $85 million to support their development.
FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!
Modular platform enables development of molecular glue stabilizers addressing intrinsically disordered proteins, a largely undrugged target classInitial discovery pipeline focused on high-value targets in oncologySAN FRANCISCO--(BUSINESS WIRE)--Ambagon Therapeutics, a biotechnology company unlocking intrinsically di...
Modular platform enables development of molecular glue stabilizers addressing intrinsically disordered proteins, a largely undrugged target class Initial discovery pipeline focused on high-value